Improving Product Value & Patient Outcomes.
Be ready for the paradigm shift
Implementation of HTA bodies and increased regulatory requirements results in a paradigm shift for medical devices. Each individual device must deliver tangible and quantifiable value e.g. addressing an unmet need, improving efficiency or effectiveness, or reducing costs.
Therefore, it is important to incorporate these value outcomes in your clinical trials and align these with your overall value generation- and communication strategies to achieve market access- and commercial success.
Market Access Activities
At NHTA we can support your MedTech market access activities from strategy to
implementation. Our services include:
Six reasons why devices differ from drugs
While medical technologies and pharmaceuticals share some similarities, it is import to acknowledge the differences between the two on several key elements. E.g. research and development models vary greatly between the two industries. Further, the regulatory, payment, and reimbursement landscape for MedTech is equally different from Pharma, making the device market much more diverse. Therefore, your HEOR and market access processes, from strategy to implementation, are crucial to obtain and secure long- term market access success.
Below are six reasons why devices differ from pharmaceuticals and why you need to approach the HEOR and market access process for devices different compared to pharmaceuticals.